PS02.246: SURGICAL OUTCOMES OF SURGICAL T4B THORACIC ESOPHAGEAL CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 192-192
Author(s):  
Norihisa Uemura ◽  
Tetsuya Abe ◽  
Eiji Higaki ◽  
Takahiro Hosoi ◽  
Byonggu An
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factor ◽  
Surgical Outcomes ◽  
Curative Resection ◽  
Conflicts Of Interest ◽  
Post Treatment ◽  
R0 Resection ◽  
Preoperative Treatment ◽  
Thoracic Esophageal Cancer ◽  
Significant Difference

Abstract Background Patients with surgical T4b (sT4b) thoracic esophageal cancer undergo exploratory thoracotomy or non-curative resection. However, in some cases, it is difficult to decide whether to perform exploratory thoracotomy without resection, or perform non-curative resection to the extent possible. The purpose of this retrospective study was to analyze surgical outcomes of sT4b thoracic esophageal cancer to clarify the optimal treatment strategy. Methods A total of 12 patients with sT4b thoracic esophageal cancer underwent exploratory thoracotomy (n = 7) or non-curative resection (n = 5) between January 2011 and December 2015. Of the seven patients who underwent exploratory thoracotomy, two underwent bypass surgery. In the five patients who underwent non-curative resection, gastric reconstruction was performed. Clinical data from these 12 patients were analyzed retrospectively. Results Compared to the seven patients who underwent exploratory thoracotomy (Ex group), the five patients who underwent non-curative resection (NC group) had a significantly longer period until the start of post-treatment (median, 23/57 (Ex/NC) days; P = 0.0027). No significant difference was observed in the postoperative survival period between the two groups (Median survival time (MST), 9/12 (Ex/NC) months; P = 0.55). In the prognostic factor analysis, patients with progressive disease (PD) responsiveness to preoperative treatment had a significantly poorer prognosis (MST, 13.5/5.5 (partial response-stable disease/PD) months; P = 0.01). On the other hand, patients with cStage 3 disease and who received postoperative chemoradiotherapy had a relatively good prognosis (cStage 3/4; MST 12.5/5.5 month, P = 0.09, postoperative chemoradiotherapy received/not received; MST 13/5 month, P = 0.11). The period until the start of post-treatment was not a prognostic factor. Conclusion Responsiveness to preoperative treatment was found to be a prognostic factor in patients with sT4b thoracic esophageal cancer. Thus, if patients show a poor response to preoperative treatment, R0 resection should be performed without exploratory thoracotomy. On the contrary, for patients with a good response to preoperative treatment, administration of post-operative chemoradiotherapy should be considered, while maintaining performance status without causing serious secondary injury. Disclosure All authors have declared no conflicts of interest.

PS01.178: ANALYSIS OF SURGICAL OUTCOME OF COMBINED RESECTION OF ADJACENT ORGANS IN ESOPHAGEAL CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 100-100
Author(s):  
Koji Tanaka ◽  
Makoto Yamasaki ◽  
Tomoki Makino ◽  
Yasuhiro Miyazaki ◽  
Tsuyoshi Takahashi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Survival Rate ◽  
Blood Vessel ◽  
Conflicts Of Interest ◽  
R0 Resection ◽  
Therapeutic Effects ◽  
Preoperative Treatment ◽  
Combined Resection ◽  
Significant Difference ◽  
T4 Esophageal Cancer

Abstract Background If the cancer remains after chemotherapy or chemoradiotherapy for cT4b esophageal cancer, curative resection is sometimes performed. In cases where T4 is not released, combined resection of adjacent organs is necessary for R0 resection. But its significance is controversial. The aim of this study is to examine the significance of combined resection of adjuacent organs for T4 esophageal cancer. Methods Of the 209 patients who were diagnosed as cT4b esophageal cancer finally resected from 2000 to 2015, the relationship between clinicopathological factors and prognosis was retrospectively analyzed in 32 patients who underwent combined resection of T4 adjuacent organs. Results Preoperative factors: Ce/Ut/Mt/Lt = 10/14/6/2, cN Yes/No = 29/4, cM Yes/No = 7/25, preoperative treatment Yes/No = 32/0, type of preoperative treatment: chemotherapy/chemotherapy + CRT/CRT = 11/11/10, clinical response: responder/nonresponder = 22/10, T4 Organ: airway (trachea, bronchus)/blood vessel (aorta, large vessel)/gastrointestinal (pancreas, liver) = 28/2/2. Organ of ombined resection: airway/blood vessel/airway + blood vessel/digestive organ = 21/7/1/4. Postoperative factors: pT: 0/3/4 = 4/11/17. pN: 0/1–3 = 9/23, pM: 0/1 = 25/7. The 3-year overall survival rate (3yOS) of 32 patients was 31.2%. Preoperative treatment clinical effect: 3yos of responder/nonresponder = 47.8%/0%, which was significantly better in the responder(P = 0.013). Resection of respiratory tract: 3yos of yes/no = 27.3%/45.7%, (P = 0.071). There was no significant difference in prognosis regardless of cN, cM and pN status. 3yOS of pM 0/1 = 40.7%/0% (P = 0.030) and was significantly better in pM0. Multivariate analysis of OS revealed that the therapeutic effects (OR: 3.49, P = 0.040), resection of the trachea (OR: 3.10, P = 0.017) were independent prognostic factors. Conclusion Even in ct4b cases of combined resection of adjacent oragan, the 3-year survival rate was relatively good. However, the prognosis of cases with poor preoperative therapeutic effect and cases with tracheal complication were poor. It seems necessary to judge surgical indication carefully. Disclosure All authors have declared no conflicts of interest.

RA07.05: DIAGNOSTIC VALUE OF INTRAOPERATIVE ULTRASONOGRAPHY IN ASSESSING THORACIC RECURRENT LARYNGEAL NERVE LYMPH NODES IN PATIENTS WITH ESOPHAGEAL CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 35-35
Author(s):  
Hong Yang
Keyword(s):  
Esophageal Cancer ◽  
Recurrent Laryngeal Nerve ◽  
Predictive Value ◽  
Conflicts Of Interest ◽  
Nodal Metastasis ◽  
Laryngeal Nerve ◽  
Intraoperative Ultrasonography ◽  
Nodal Metastases ◽  
Thoracic Esophageal Cancer ◽  
Significant Difference

Abstract Background To evaluate the ability of intraoperative ultrasonography (IU) to detect recurrent laryngeal nerve (RLN) nodal metastases in esophageal cancer patients. Methods Sixty patients with esophageal cancer underwent IU, computed tomography (CT), and endoscopic ultrasonography (EUS) to assess for RLN nodal metastasis. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were compared. Results The sensitivities of IU, CT, and EUS in diagnosing right RLN nodal metastases were 71.4%, 14.3%, and 30.0%, respectively, and a significant difference among these three examinations was observed (c2 = 10.077, P = .006). The specificities of IU, CT, and EUS for diagnosing right RLN nodal metastasis were 67.4%, 97.8%, and 95.0%, respectively, and a significant difference was observed (c2 = 21.725, P < .001). No significant differences in either PPV or NPV were observed when diagnosing right RLN nodal metastases. For diagnosis of left RLN lymph nodal metastases, the sensitivities of IU, CT, and EUS were 91.7%, 16.7%, and 40.0% respectively. There was a significant difference among these diagnostic sensitivities (c2 = 14.067, P = .001). The specificities of IU, CT, and EUS for diagnosis of left RLN nodal metastases were 79.2%, 100%, and 82.5%, respectively and a significant difference was observed (c2 = 10.819, P = .004). No significant differences were observed in PPV or NPV for these examinations when diagnosing left RLN nodal metastases. Conclusion Intraoperative ultrasonography showed superior sensitivity compared with preoperative CT or EUS in detecting RLN lymph node metastasis in patients with thoracic esophageal cancer. Disclosure All authors have declared no conflicts of interest.

PS02.141: RESULTS AND PROSPECTS OF SALVAGE SURGERY AFTER DEFINITIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 160-161
Author(s):  
Yoshihiro Nabeya ◽  
Isamu Hoshino ◽  
Matsuo Nagata ◽  
Nobuhiro Takiguchi ◽  
Atsushi Ikeda ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Conflicts Of Interest ◽  
Salvage Surgery ◽  
Disease Free Survival ◽  
Residual Tumor ◽  
Postoperative Recurrence ◽  
Hospital Death ◽  
R0 Resection ◽  
Definitive Chemoradiotherapy ◽  
Significant Difference

Abstract Background Salvage surgery for esophageal cancer (squamous cell carcinoma) patients with locoregional failure after definitive chemoradiotherapy (dCRT) is high risk, and no surgical consensus has been established. We evaluated our 2 procedures of salvage surgery for failure which was confirmed by GS, CT, and PET: [SE] esophagectomy followed by reconstruction for patients ≤ 80 yo, without cT4 at the initial presentation, and whose recurrent/residual tumor can be removed as a R0 resection, and [SL] dissection of only metastatic abdominal lymph nodes for patients without any other failure. Methods All patients received dCRT ≥ 50 Gy followed by salvage surgery. In 17 patients who underwent SE from 2009 to 2014, prophylactic dissection of cervical or 106 tbL nodes was often omitted, poststernal route was preferred, LigasureTM was routinely used, and aggressive nutritional intervention with enteral nutrition was perioperatively supplied. In SL for 5 patients until 2016, No. 3 and 7 nodes were removed. Results [SE] Sixteen patients received R0 resection. Postoperative complications were noted in 6 patients (35%), and pleural effusion was the most common (24%). However, neither anastomotic leakage nor in-hospital death developed. Median overall survival (OS) time is 44 months, and provisional 5-year OS rate is 41%. While 7 patients died of esophageal caner, one died from another caner and 3 died from other illness. Tentative 5-year disease-free survival (DFS) rate is 54%. Between cases with relapse after CR and cases with residual tumor, no significant difference was found in postoperative recurrence (2/8 vs. 5/9, P = 0.33) and survival (provisional 5-year OS rate: 50 vs. 33%, P = 0.45/provisional 5-year DFS rate: 70 vs. 40%, P = 0.22), while the relapsed patients after CR showed a little better outcome. [SL] Three patients have no relapse for 60/36/18 months after SL. One developed bone metastasis in 54 months after SL. One patient developed repeated abdominal recurrence and underwent SL again. Conclusion SE can be safely performed with strict planning, secure surgery and appropriate perioperative care. SL can also be beneficial as a less invasive salvage surgery to selected patients. Strict decision-making and appropriate postoperative follow-up method with attention to other diseases should be established based on further studies. Disclosure All authors have declared no conflicts of interest.

scholarly journals Significance of Tumor Length as Prognostic Factor for Esophageal Cancer

2013 ◽  
Vol 98 (3) ◽  
pp. 234-240 ◽  
Author(s):  
Arife Zeybek ◽  
Abdullah Erdoğan ◽  
Kemal Hakan Gülkesen ◽  
Makbule Ergin ◽  
Alpay Sarper ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Specific Treatment ◽  
Disease Free Survival ◽  
Curative Surgery ◽  
Thoracic Esophageal Cancer ◽  
Clinicopathologic Characteristics ◽  
Term Survival ◽  
Tumor Length ◽  
Significant Difference

Abstract Our study indicated the relationship between tumor length and clinicopathologic characteristics as well as long-term survival in esophageal cancer. A total of 116 patients who underwent curative surgery for thoracic esophageal cancer with standard lymphadenectomy in 2 fields between 2000 and 2010 were included in the study. The medical records of these patients were retrospectively reviewed. The patients with tumor length ≥3 cm had a highly significant difference in the involvement of adventitia and lymph node stations. The patients with tumor length ≤3 cm had significantly lower rates of involvement of the adventitia and lymph node stations. Tumor length could have a significant impact on both the overall survival and disease-free survival of patients with resected esophageal carcinomas and may provide additional prognostic value to the current tumor, node, and metastasis staging system before patients receive any cancer-specific treatment.

Recurrence patterns of gastric cancer in the era of preoperative therapy.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 119-119
Author(s):  
Naruhiko Ikoma ◽  
Hsiang-Chun Chen ◽  
Xuemei Wang ◽  
Mariela A. Blum Murphy ◽  
Jeannelyn Estrella ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Therapy ◽  
Curative Resection ◽  
Median Number ◽  
Distant Recurrence ◽  
Survival Duration ◽  
R0 Resection ◽  
Preoperative Treatment ◽  
Clinicopathologic Factors ◽  
Gastric Cancer Patients

119 Background: The purpose of this study was to determine the disease sites and survival durations of patients who developed a recurrence after undergoing gastrectomy for adenocarcinoma. Methods: We collected data from a prospectively maintained database of gastric cancer patients who underwent potentially curative resection of gastric or gastroesophageal cancer at our institution from 1995-2014. Univariate and multivariate analyses were performed to determine the associations between clinicopathologic factors and treatment outcomes. Results: We identified 488 patients who underwent R0 resection of localized gastric cancer. The median age was 63 years (IQR, 53-71 years), and 60% were male. The most common EUS stages were T3 (58%) and N0 (61%). Preoperative treatment was used in 61% of patients. The majority (76%) of patients underwent extended (D1+/D2) lymphadenectomy, and the median number of examined lymph nodes was 21 (IQR, 14-29). Of the 488 patients, 125 (26%) experienced recurrence during follow up. The sites of recurrence were locoregional (n = 19 [15%]), peritoneal (n = 61 [49%]), and non-peritoneal distant at any site (n = 67 [53.6%]). The site of recurrence was not associated with neoadjuvant therapy (p = 0.35). The median time from the primary resection to recurrence was 2.7 years (95% CI, 0.8-3.2 years) for locoregional, 1.3 (0.7-1.7) for peritoneum, and 0.6 (0.5-0.9) for distant disease (p = 0.01). The median overall survival time from recurrence was 1.0 year (95% CI, 0.5-3.1 years) for locoregional, 0.6 (0.4-0.9) for peritoneum, and 0.8 (0.5-1.0) for distant recurrence (p = 0.05). A multivariate analysis revealed that age ≥ 65 years (HR, 1.52 [95% CI, 1.12-2.05 years]; p = 0.01) and advanced EUS T stage (3.06 [2.10-4.46]; p < 0.001) were associated with a shorter recurrence-free survival duration. Conclusions: Peritoneal carcinomatosis was the most common site of recurrence after curative resection of gastric cancer, with associated poor survival, and was not associated with the use of neoadjuvant therapy. Future trials should focus on treatment of the peritoneum, which may improve the survival of patients with advanced gastric cancer.

scholarly journals 98% IGHV Gene Identity Is Still the Optimal Cutoff to Predict the Prognosis of Chronic Lymphocytic Leukemia Patients in China

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5545-5545
Author(s):  
Yi Xia ◽  
Ke Shi ◽  
Qian Sun ◽  
Chun Qiao ◽  
Huayuan Zhu ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Chronic Lymphocytic Leukemia ◽  
Conflicts Of Interest ◽  
Somatic Hypermutation ◽  
Lymphocytic Leukemia ◽  
Study Cohort ◽  
Optimal Cutoff ◽  
Entire Cohort ◽  
Mutational Status ◽  
Significant Difference

Abstract Background: Immunoglobulin heavy chain variable region (IGHV) has been an important prognostic factor for chronic lymphocytic leukemia (CLL) for decades. 98% being a cut-off value for IGHV is a mathematical choice and researches on the best cut-off value have never been stopped. Chinese CLL patients are known to differ from Caucasian CLL patients on both clinical and genetical features. However, the optimal cutoff for IGHV mutational status has not yet been studied in this particular ethnic group. Method: We carried out a study on 595 Chinese CLL patients in order to find out whether 98% is the best cut-off value for IGHV in Chinese CLL patients. Genomic DNA from peripheral blood or bone marrow was subjected to PCR amplification following the IGH Somatic Hypermutation Assay v2.0 protocol (InVivoScribe). Sequences were aligned to ImMunoGeneTics/V-QUEry and Standardization (IMGT/-VQUEST) database. Result: 600 sequences were received after IGHV rearrangement sequencing. IGHV3-23, IGHV4-34, IGHV3-7, IGHV4-39 and IGHV1-69 were the most frequently used IGHV genes. 352 (58.7%) cases were IGHV-mutated while 248 (41.3%) cases were IGHV-unmutated if the classical 98% classification by ERIC was used. In order to determine the optimal cut-off value, we used 1% as the interval to divide the entire cohort into 7 groups according to the mutational rate, which were <95%, 95%-95.99%, 96%-96.99%, 97%-97.99%, 98%-98.99%, 99%-99.99% and 100% respectively. Binet A patients had a relatively indolent course of disease and cases with different IGHV mutational rates had no significant differences in time to first treatment (TTFT) apart from truly unmutated (100%) cases. For the whole study cohort, significant difference appeared at 98% interval (P<0.001 and P=0.005 for TTFT and OS respectively) while intervals less than 98% had no significant difference compared with the <95% group. Similarly, there was no clear dissimilarities among 98%, 99% and 100% intervals (Table 1a and b). All the other prognostic factors including del(17p), del(11q), TP53 mutation, MYD88 mutation, NOTCH1 mutation, SF3B1 mutation, CD38, ZAP-70, Binet staging, gender, β2-microglobulin and EBV-DNA were differently distributed between group <98% and group ³98%, but not among subgroups in ³98%. In multivariate analysis, the 98% IGHV was also an independent prognostic factor for TTFT and OS. Conclusion: 98% is the optimal cutoff value for IGHV mutational status to predict the prognosis of CLL patients in China. Table 1. Table 1. Disclosures No relevant conflicts of interest to declare.

PS02.129: BRAIN METASTASIS FROM THORACIC ESOPHAGEAL CANCER AT A SINGLE INSTITUTE

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 157-158
Author(s):  
Motohiro Hirao ◽  
Eiichi Tanaka ◽  
Y Okita ◽  
T Fujinaka ◽  
K Nishikawa ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Conflicts Of Interest ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Univariate Analysis ◽  
Clinical Information ◽  
Esophageal Resection ◽  
Average Score ◽  
Thoracic Esophageal Cancer

Abstract Background Brain metastases (BM) from esophageal cancer (EC) are rare. Despite of an advance of treatments for the patients with BM from EC, life expectancy and quality of life of these patients are still poor. We present an overview of the patients with BM from EC at a single institute. Methods We retrospectively identified 10 patients with BM from EC treated with surgery, radiation, or a combination of multidisciplinary therapies at Osaka National Hospital between 2003 and 2017 for stages IIb through IV of primary EC (follow-up, > 157 days). Medical records were reviewed to collect demographic and clinical information. Results Median age at diagnosis of BM was 63.5 years (range, 53–79 years). 9 patients were male, and 7 patients had squamous cell carcinoma of EC at the primary esophageal resection. Median overall survival from the commencements of therapy for BM was 156 days (range, 17–5404 days). The interval between the primary esophagectomy and the start of therapy for BM from EC was 298 days (range, 64–860 days). The average score of Karnofsky performance status (KPS) just before a diagnosis of BM was 75 (range, 50–90). On univariate analysis, the patients with the lower score of KPS (P = 0.01) or the shorter interval between the primary esophageal surgery and the start of therapy for BM (P = 0.06) were found to have worsened survival after the therapy for BM from EC. Conclusion The patients who had a poor KPS just before a diagnosis of BM, or the shorter interval between the esophagectomy for the primary EC and the start of therapy for BM, had poor prognosis. Disclosure All authors have declared no conflicts of interest.

Does primary site of colorectal cancer become a prognostic factor of patients undergoing curative resection of liver metastases?

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 772-772 ◽  
Author(s):  
Rika Kizawa ◽  
Yasushi Ichikawa ◽  
Fumitaka Kumamoto ◽  
Yu Sawada ◽  
Ryusei Matsuyama ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Colon Cancer ◽  
Liver Metastasis ◽  
Prognostic Factor ◽  
Liver Metastases ◽  
Curative Resection ◽  
Cox Regression ◽  
Univariate Analysis ◽  
Primary Site ◽  
Significant Difference

772 Background: The comparison of prognosis between right and left-sided colon cancer (RC, LC) has recently attracted a lot of attention. We examined whether primary location of colo-rectal cancer represents a prognostic factor of patients received curative resection of liver metastasis. Methods: We reviewed all patients undergoing resection of liver metastasis of colo-rectal cancer from1992 to 2013 in the 2 YCU hospitals, and selected eligible 377 patients (59 [15.6 %] with RC, 318 [84.4 %] with LC) undergoing R0 or 1 resection of primary and metastatic lesions. Patients with transverse colon cancer were excluded. We stratified patients according to previously-reported prognostic factors of hepatic metastasis resection, and conducted univariate analysis by Log Rank test to compared overall survival (OS) in each stratum. Using those results, independent factors affecting OS were determined by multivariable Cox regression. Results: The median OS of 377 patients was 66 months, and disease free survival (DFS) was 11.6 months. Univariate analysis revealed that the number and maximum diameter of liver metastasis, existence of other metastasis apart from liver, CEA, and having pre- or post- operative chemotherapy showed significant difference of OS. Primary site did not show significant difference of OS (p = 0.547), but median OS of LC (67 months) was 24 months longer than of RC. As for DFS, there was no significant difference between RC and LC (10.75 vs. 11.6 months, p = 0.873). Multivariate Cox regression analysis was conducted using former factors showing significant difference and primary site. Then primary site was an independent prognostic factor (p = 0.047). LC showed a lower risk than RC (HR: 0.675). Conclusions: The primary site did not affect DFS, but could become a prognostic factor of OS with patients undergoing curative resection of liver metastases. It suggested that curative resection of liver metastases could contribute to prolong survival, regardless of RC or LC. And there is some possibility that the primary site affects prognosis after post-operative recurrence of colo-rectal cancer liver metastases.

Evaluation of the ratio of plasma fibrinogen to platelet in resectable pancreatic cancer.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 756-756
Author(s):  
Yusuke Arakawa ◽  
Mitsuo Shimada ◽  
Yuji Morine ◽  
Satoru Imura ◽  
Tetsuya Ikemoto ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factor ◽  
Curative Resection ◽  
Operative Time ◽  
Plasma Fibrinogen ◽  
Resectable Pancreatic Cancer ◽  
Free Survival ◽  
Neutrophil Lymphocyte Ratio ◽  
Significant Difference ◽  
Resectable Gastric Cancer

756 Background: Several prognostic factors were reported in pancreatic cancer such as neutrophil lymphocyte ratio (NLR), platelet lymphocyte ration (PLR) modified GPS. Fibrinogen platelet ratio (FPR) was reported as one of the prognostic factor of resectable gastric cancer (Surgery today 2019). In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods: Between 2004 and 2019, one hundred and sixty-three patients in our institution with curative resection for pancreatic cancer were enrolled in this retrospective study. The cases of non-curative resection were excluded. The FPR was calculated with the preoperative plasma fibrinogen and the platelet counts. Cut-off value was decided with ROC curve. The patients were divided into high and low FPR group according to cut-off value. Results: The cut-off value of FPR was 25.51. In age, gender, BMI, operative factors including operative type, amount of blood loss and operative time, there was no significant difference between these two groups. Patients in low FPR group had significantly better overall survival (OS) rates and relapse-free survival (RFS) rates compared with high FPR group (p < 0.05). On multivariate analysis, the high FPR, CA19-9 > 300 U/ml and receipt of adjuvant chemotherapy were independent risk factor of post-operative recurrence. Conclusions: The FPR might be a prognostic factor of patients with resectable pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document